Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Université de Montréal

$100,000.00

Control of hematopoietic cell fate by LMO2

EF 2016-17

Résumé
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Our efforts are aimed at understanding how the LMO2 oncogene induce T-ALL. This oncogene is activated in childhood T-ALL by different mechanisms, one of which was widely discussed in the context of a gene therapy trial to correct for severe immunodeficiency, causing inadvertent activation of LMO2. In particular, two patients who eventually developed T-ALL showed T-cell hyperproliferation 2-4 months after gene transfer. We have recently uncovered a novel function for LMO2 in directly regulating how the genetic material is duplicated, thereby explaining this hyperproliferation. In summary, we now show that LMO2 dictates blood cell identity by governing two essential properties in the cell, gene expression and genome duplication. Because of this dual function, LMO2 is a major oncogene in T-ALL. We propose that LMO2 is an important networking center in the cell. In this research proposal, we will build on our novel understanding of LMO2 function to chase the protein and gene networks that interact with LMO2, using state of the art technologies. We will also identify how cells counter the potentially damaging effect of LMO2. With the advent of powerful technologies, we now have unprecedented opportunities to uncover gene and protein networks. It is now essential to design and use models that are most representative of human acute leukemia. The research will open a novel and unexpected perspective on our understanding of cell transformation by oncogenes in blood cancers and in other types of cancers as well.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
366612
Name
Hoang Trang K
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Control of hematopoietic cell fate by LMO2
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Genetic Collaboration; Knock-Out Mice; Leukemia; Lmo1 Oncogene; Lmo2 Oncogene; Pre-Leukemic Stem Cells; Scl/Tall; T-All; Thymocyte; Transgenic Mice
Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Our efforts are aimed at understanding how the LMO2 oncogene induce T-ALL. This oncogene is activated in childhood T-ALL by different mechanisms, one of which was widely discussed in the context of a gene therapy trial to correct for severe immunodeficiency, causing inadvertent activation of LMO2. In particular, two patients who eventually developed T-ALL showed T-cell hyperproliferation 2-4 months after gene transfer. We have recently uncovered a novel function for LMO2 in directly regulating how the genetic material is duplicated, thereby explaining this hyperproliferation. In summary, we now show that LMO2 dictates blood cell identity by governing two essential properties in the cell, gene expression and genome duplication. Because of this dual function, LMO2 is a major oncogene in T-ALL. We propose that LMO2 is an important networking center in the cell. In this research proposal, we will build on our novel understanding of LMO2 function to chase the protein and gene networks that interact with LMO2, using state of the art technologies. We will also identify how cells counter the potentially damaging effect of LMO2. With the advent of powerful technologies, we now have unprecedented opportunities to uncover gene and protein networks. It is now essential to design and use models that are most representative of human acute leukemia. The research will open a novel and unexpected perspective on our understanding of cell transformation by oncogenes in blood cancers and in other types of cancers as well.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hoang, Trang K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~